Roivant SciencesROIV +0.35%55 Market Cap is $24,591.85 Mil as of Jun. 29, 2026. GuruFocus rates ROIV with a GF Score™ of 55/100 and a GF Value™ of $10.45 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 1,428 Biotechnology companies, Roivant Sciences ranks better than 99.09% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Roivant Sciences's share price for the quarter that ended in Mar. 2026 was $27.7. Roivant Sciences's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 720.35 Mil. Therefore, Roivant Sciences's market cap for the quarter that ended in Mar. 2026 was $19,953.75 Mil.
Roivant Sciences's quarterly market cap
increased
from Sep. 2025 ($10,435.12 Mil) to Dec. 2025 ($15,400.25 Mil) and
increased
from Dec. 2025 ($15,400.25 Mil) to Mar. 2026 ($19,953.75 Mil).
Roivant Sciences's annual market cap
declined
from Mar. 2024 ($8,502.39 Mil) to Mar. 2025 ($7,022.01 Mil) but then
increased
from Mar. 2025 ($7,022.01 Mil) to Mar. 2026 ($19,953.75 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Roivant Sciences's Enterprise Value for Today is $21,172.50 Mil.
Roivant Sciences (NAS:ROIV) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Roivant Sciences Market Cap Related Terms
Roivant Sciences Market Cap Historical Data
* Premium members only.
The historical data trend for Roivant Sciences's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Roivant Sciences's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Roivant Sciences Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Roivant Sciences's Market Cap distribution charts can be found below:
* The bar in red indicates where Roivant Sciences's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Roivant Sciences's Market Cap for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Roivant Sciences (ROIV) has a Market Cap of $24,591.85 Mil as of Jun. 29, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Roivant Sciences and its competitors. According to the industry distribution chart, Roivant Sciences ranks #13 out of 1428 companies in the Biotechnology industry, placing it in the top 0.90000000000001%.
Is Roivant Sciences' Market Cap too high?
Roivant Sciences' current Market Cap is $24,591.85 Mil. The Biotechnology industry median Market Cap is 114.03. Roivant Sciences' value of $24,591.85 Mil is 21465.7% above this industry median. Based on the distribution chart, Roivant Sciences ranks #13 out of 1428 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Roivant Sciences has a GF Score™ of 55/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Roivant Sciences' Market Cap compare to RPRX and BNTX?
According to the Biotechnology industry distribution chart, Roivant Sciences ranks #13 out of 1428 companies for Market Cap. This places Roivant Sciences in the top 1% of its industry — outperforming the majority of peers. The industry median Market Cap is 114.03. Roivant Sciences' value of $24,591.85 Mil is 21465.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 114.03, based on 1,428 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Roivant Sciences's current Market Cap of $24,591.85 Mil is 21465.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Roivant Sciences and its competitors. For the Biotechnology industry, the median Market Cap is 114.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Roivant Sciences's current Market Cap is $24,591.85 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Roivant Sciences stock overvalued right now?
Based on GuruFocus' analysis, Roivant Sciences (ROIV) is currently considered Significantly Overvalued. The stock's GF Value™ is $10.45, compared to a current price of $34.19 — trading 227.2% above its estimated fair value. The current Market Cap is $24,591.85 Mil and 21465.7% above the Biotechnology industry median of 114.03. Roivant Sciences' overall GF Score™ is 55/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Roivant Sciences (ROIV), the current Market Cap is $24,591.85 Mil as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Roivant Sciences (ROIV) Overvalued in 2026?
Based on GuruFocus' analysis, Roivant Sciences stock appears to be overvalued.
The current stock price of $34.19 is trading 227.2% above its estimated GF Value™ of $10.45.
GuruFocus considers Roivant Sciences to be Significantly Overvalued.
Key valuation signals for ROIV:
Market Cap: $24,591.85 Mil
GF Value™: $10.45 vs. price of $34.19 (227.2% above fair value)
Industry Position: 21465.7% above the Biotechnology median (#13 of 1428)
No single metric tells the full story. See the ROIV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
55GF Score
Get the complete analysis for ROIV
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROIV has been successfully added to your 
